Given drugs that induce protein degradation of PML-RARA lead to high response rates in acute promyelocytic leukemia (APL)61–65, we hypothesized that the PML-RARA fusion may escape protein degradation through degron loss, but was missed in our systematic analysis. The gene discussed is PML; the disease is acute promyelocytic leukemia.